The National Gene Vector Biorepository: Eleven Years of Providing Resources to the Gene Therapy Community

Human Gene Therapy
Volume 31, Issue 3-4 / February 2020
https://www.liebertpub.com/toc/hum/31/3-4

 

Review
The National Gene Vector Biorepository: Eleven Years of Providing Resources to the Gene Therapy Community
Kenneth Cornetta, Lorraine Matheson, Ryan Long, and Lisa Duffy
Pages:145–150
Published Online:30 January 2020
Abstract
The National Gene Vector Biorepository (NGVB) program has been highly accessed by gene therapy investigators. The reagent repository has distributed over 1,000 reagents to 397 investigators. The Pharmacology/Toxicology Archive contains over 36,000 specimens from a variety of adeno-associated virus (AAV), adenoviral, and other pharmacology/toxicology studies. NGVB also maintains a searchable database of gene therapy pharmacology/toxicology studies to promote data sharing. NGVB has provided Food and Drug Administration (FDA)-mandated replication-competent virus testing for over 70 clinical trials. From 2008 to 2018, there have been 114 publications acknowledging the NGVB. It is unlikely that any other National Institutes of Health (NIH)-funded program has served as many gene therapy investigators as the NGVB.